Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less

被引：0
|
作者：
Das, A. [1 ]
Dean, A. [1 ]
Travers, N. [1 ]
Johansson, M. [1 ]
Yusoff, I. [1 ]
机构：
[1] St John God Subiaco, Bendat Canc Ctr, Subiaco, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
182P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
    Vienot, Angelique
    Beinse, Guillaume
    Louvet, Christophe
    de Mestier, Louis
    Meurisse, Aurelia
    Fein, Francine
    Heyd, Bruno
    Cleau, Denis
    d'Engremont, Christelle
    Dupont-Gossart, Anne-Claire
    Lakkis, Zaher
    Tournigand, Christophe
    Bouche, Olivier
    Rousseau, Benoit
    Neuzillet, Cindy
    Bonnetain, Franck
    Borg, Christophe
    Vernerey, Dewi
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (10):
  • [22] Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients
    Vivaldi, C.
    Vasile, E.
    Fornaro, L.
    Caparello, C.
    Musettini, G.
    Pasquini, G.
    Lencioni, M.
    Ricci, S.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S456 - S457
  • [23] Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis
    Lino, Aline da Rocha
    Abrahao, Carina Meira
    Brandao, Raphael Moreira
    Gomes, Jessica Ribeiro
    Ferrian, Andrea Malta
    Cesar Machado, Marcel Cerqueira
    Buzaid, Antonio Carlos
    Maluf, Fernando Cotait
    Peixoto, Renata D'Alpino
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (05) : 511 - 515
  • [24] Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
    Liu, Yuxiao
    Guo, Xiaofan
    Xu, Peijun
    Song, Yuning
    Huang, Jing
    Chen, Xingyun
    Zhu, Wenbo
    Hao, Jihui
    Gao, Song
    CANCER BIOLOGY & MEDICINE, 2024, 21 (09) : 799 - 812
  • [25] Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
    Yuxiao Liu
    Xiaofan Guo
    Peijun Xu
    Yuning Song
    Jing Huang
    Xingyun Chen
    Wenbo Zhu
    Jihui Hao
    Song Gao
    Cancer Biology & Medicine, 2024, 21 (09) : 799 - 812
  • [26] Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma
    Ulusakarya, Ayhan
    Teyar, Nahla
    Karaboue, Abdoulaye
    Haydar, Mazen
    Krimi, Sarra
    Biondani, Pamela
    Gumus, Yusuf
    Chebib, Amale
    Almohamad, Wathek
    Morere, Jean-Francois
    MEDICINE, 2019, 98 (16)
  • [27] Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
    Sadaka, Shiori
    Iwashita, Takuji
    Fujii, Hironori
    Kato-Hayashi, Hiroko
    Ohata, Koichi
    Uemura, Shinya
    Shimizu, Masahito
    Suzuki, Akio
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (19)
  • [28] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [29] Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel
    McSweeney, T.
    Das, A.
    O'Mahony, A.
    O'Tighearnaigh, F.
    O'Byrne, L.
    Feely, M.
    Passmore, E.
    Keane, S.
    Lanigan, S.
    Fitzgerald, S.
    Browne, T.
    De Beer, V.
    Dean, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S133 - S133
  • [30] A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma
    Reni, M.
    Berardi, R.
    Mambrini, A.
    Pasetto, L.
    Cereda, S.
    Ferrari, V. D.
    Cascinu, S.
    Cantore, M.
    Mazza, E.
    Grisanti, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (04) : 673 - 678
12345